Sunitinib is an FDA-approved oral inhibitor of multi-target receptor tyrosine kinases and has demonstrated efficacy in the treatment of renal cell carcinoma and imatinib-resistant gastrointestinal stromal tumor [69]. Here, NTRK1 is linked to hereditary clear cell renal cell carcinoma.